Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-t
British Journal of Dermatology2016Vol. 175(2), pp. 340–347
Citations Over TimeTop 10% of 2016 papers
Jeffrey Zweegers, J.M.P.A. van den Reek, P.C.M. van de Kerkhof, Marisol E. Otero, A.L.A. Kuijpers, M.I.A. Koetsier, W.P. Arnold, M.A.M. Berends, Lizelotte J.M.T. Weppner‐Parren, Paul M. Ossenkoppele, M.D. Njoo, J.M. Mommers, P.P.M. van Lümig, R.J.B. Driessen, Wietske Kievit, E.M.G.J. de Jong
Abstract
Ustekinumab has the highest confounder-corrected long-term drug survival in psoriasis treatment, compared with adalimumab and etanercept. Higher BMI is a predictor for discontinuation due to ineffectiveness in etanercept and ustekinumab, and female sex is a consistent predictor for discontinuation due to side-effects in all three outpatient biologics.
Related Papers
- → Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry(2015)12 cited
- → Medication adherence and persistence in the treatment of rheumatoid arthritis with adalimumab and etanercept. Six years of analysis(2014)9 cited
- → Paradoxical worsening of psoriasis when switching from etanercept to adalimumab: A case series(2010)18 cited
- → Adalimumab and etanercept adherence, persistence and switch in the treatment of psoriatic arthritis: 10-year real-life analysis(2019)8 cited
- → PSS24 Cost-Effectiveness of Ustekinumab vs Etanercept for Severe Psoriasis(2011)1 cited